SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency

Area of Science:

• Genetics and Molecular Biology
• Hepatology and Pulmonology

Background:

• Alpha-1-antitrypsin (AAT) deficiency is a genetic disorder caused by SERPINA1 gene mutations, leading to defective AAT protein.
• This deficiency results in reduced AAT activity in the lungs and toxic AAT accumulation in the liver.
• Current treatments for AAT deficiency primarily focus on lung disease, with no specific therapies available for the liver complications.

Purpose of the Study:

• To investigate the potential of messenger RNA (mRNA) therapy as a treatment for Alpha-1-antitrypsin (AAT) deficiency.
• To evaluate the efficacy of SERPINA1 mRNA delivery in restoring AAT protein levels in affected tissues.

Main Methods:

• Transfection of AAT patient-derived fibroblasts and hepatocytes with SERPINA1-encoding mRNA.
• Measurement of SerpinA1 protein expression in cell culture media.
• In vivo biodistribution and protein expression studies of SERPINA1 mRNA in wild-type mice, focusing on liver and lungs.

Main Results:

• Successful detection of increased SerpinA1 protein in the media of treated AAT patient cells.
• Demonstrated biodistribution of SERPINA1 mRNA to the liver and lungs in mice.
• Confirmed SerpinA1 protein expression in the target organs (liver and lungs) following mRNA administration.

Conclusions:

• SERPINA1 mRNA therapy demonstrates potential for increasing functional AAT protein.
• This approach may offer a therapeutic strategy for both liver and lung diseases associated with AAT deficiency.
• Further research into SERPINA1 mRNA therapy could lead to new treatments for AAT deficiency patients.